SESAR
The SESAR study (led by Associate Professor Matthieu Jabaudon at Centre Hospitalier Universitaire Clermont-Ferrand, France) is a randomised, controlled study involving 700 intensive care patients with acute respiratory distress syndrome (ARDS). Treatment with inhaled sedation with sevoflurane for up to seven days is compared to intravenous propofol. The primary objective is to assess the efficacy of inhaled sedation measured as number of ventilator-free days at day 28, considering death as a competing event. The study involves 30 ICUs across France and is expected to be completed by 2025.
INASED
The INASED study (led by Dr Pierre Bailly and Professor Erwan L’Her at Centre Hospitalier Regionale Universitaire Brest, France) is a randomised, controlled study involving 250 patients who are anticipated to need mechanical ventilation in an ICU for more than 24 hours. The primary objective is to assess the incidence of delirium following inhaled sedation with isoflurane compared to intravenous propofol. The study is being carried out at 10 ICUs in France and its completion is planned for 2025.
ISCA
The ISCA study (led by Associate professor Matthieu Jabaudon, France, Associate professor Martin Schläpfer, Switzerland, Professor Rafael Badenes, Spain and Associate professor Tobias Becher, Germany) was an observational, retrospective study of 200 COVID-19-related ARDS patients. The study was conducted across 10 European and US intensive care units comparing inhaled sedation (isoflurane or sevoflurane) to intravenous sedation. The primary objective was to assess the efficacy of inhaled sedation measured as number of ventilator-free days at day 28, considering death as a competing event, link to study results.